Canaccord raised the firm’s price target on Exagen (XGN) to $8 from $7 and keeps a Buy rating on the shares. The firm said its price target increase is driven by decreased operating expenses in 2027 and beyond and Exagen believes it remains on track to deliver positive adjusted EBITDA in 4Q25.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XGN:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue